Browsing Tag
MYR301
2 posts
How a first-in-class HDV approval could support Gilead Sciences’ long-term antiviral portfolio
Find out how Hepcludex approval could strengthen Gilead Sciences’ antiviral portfolio and reshape HDV care in the U.S.
How confirmatory trial pressure could shape the future of HDV treatment markets
FDA approval gave Hepcludex a major HDV breakthrough, but confirmatory trials may decide its long-term future. Read the full analysis.